Answer given by Ms Kyriakides on behalf of the European Commission
18.12.2020
The Pharmaceutical Strategy for Europe[1], published by the Commission on 25 November 2020, proposes actions to address concerns regarding the robustness of pharmaceutical supply and manufacturing chains, including reliance on the pharmaceutical raw material and active pharmaceutical ingredients. In 2021, the Commission will launch a Structured Dialogue with representatives of pharmaceutical manufacturing value chain, Member States and patients and health professionals’ representatives in order to gain better understanding of the supply chains designs and identify their vulnerabilities. In the second phase, based on the results and data gathered, the Commission will propose concrete actions to address identified problems. The need for more transparency of the supply chains will be also taken into account by the Commission when revising the pharmaceutical legal framework, as announced in the strategy.
- [1] Communication from the Commission to the European Parliament, the Council, the European Economic and Social Committee and the Committee of the Regions,
Pharmaceutical Strategy for Europe, COM(2020) 761 final, https://ec.europa.eu/health/sites/health/files/human-use/docs/pharmastrategy_com2020-761_en.pdf